RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Pemvidutide (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Acronyms RECLAIM
- Sponsors Altimmune
Most Recent Events
- 22 May 2025 New trial record
- 19 May 2025 According to the Altimmune Media Release, company today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD).
- 19 May 2025 According to the Altimmune Media Release, Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator.